Page last updated: 2024-12-07

pyronaridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID107771
CHEMBL ID35228
CHEBI ID135951
SCHEMBL ID247252
SCHEMBL ID1650244
MeSH IDM0090219

Synonyms (51)

Synonym
pyronaridine
2-methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine
4-((7-chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol
malaridine
phenol, 4-((7-chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)-
benzonaphthyridine 7351
CHEBI:135951
CHEMBL35228
4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one
NCGC00246187-01
BBL010793
4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
STK597795
AKOS005518849
pyronaridine [inn]
74847-35-1
unii-td3p7q3sg6
td3p7q3sg6 ,
NCGC00246187-02
4-((7-chloro-2-methoxybenzo(b)(1,5)naphthyridin-10-yl)amino)-2,6-bis((pyrrolidin-1-yl)methyl)phenol
pyronaridine [who-dd]
pyronaridine [mi]
SCHEMBL247252
4-[(7-chloro-2-methoxy-benzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
MLS006011911
smr004703513
SCHEMBL1650244
4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(1-pyrrolidinylmethyl)-1-cyclohexa-2,5-dienone;phosphoric acid
cid_20833062
4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one;phosphoric acid
4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidinomethyl)cyclohexa-2,5-dien-1-one;phosphoric acid
bdbm53353
4-[(7-chloranyl-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one;phosphoric acid
AB00876285_04
4-({7-chloro-2-methoxy-1h,5h-benzo[b]1,5-naphthyridin-10-yl}imino)-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one
mfcd01748123
4-((7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino)-2,6-bis(pyrrolidin-1-ylmethyl)phenol
DB12975
BCP19128
malaridine;benzonaphthyridine 7351
gtpl10086
DTXSID60996354
EX-A2938
Q7263674
AMY18340
FT-0778221
NCGC00246187-06
ZCA84735
CS-0003536
HY-14749
AT33644

Research Excerpts

Overview

Pyronaridine (PYR) is an erythrocytic schizonticide with a potent antimalarial activity against multidrug-resistant Plasmodium. It has received renewed interest as a partner drug in artemisinin-based combination therapy.

ExcerptReferenceRelevance
"Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole."( Pyronaridine: a review of its clinical pharmacology in the treatment of malaria.
Chu, WY; Dorlo, TPC, 2023
)
3.07
"Pyronaridine (PYR) is an erythrocytic schizonticide with a potent antimalarial activity against multidrug-resistant Plasmodium. "( Pyronaridine: An update of its pharmacological activities and mechanisms of action.
Bailly, C, 2021
)
3.51
"Pyronaridine is a known antimalarial drug that has received renewed interest as a partner drug in artemisinin-based combination therapy."( Quantification of the antimalarial drug pyronaridine in whole blood using LC-MS/MS - Increased sensitivity resulting from reduced non-specific binding.
Blessborn, D; Day, NPJ; Kaewkhao, K; Song, L; Tarning, J; White, NJ, 2017
)
1.44
"Pyronaridine-artesunate is a novel artemisinin-based combination therapy. "( Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial.
Choy, F; Makio, N; Mens, P; Okach, S; Omweri, G; Osoti, V; Roth, JM; Sawa, P; Schallig, HDFH, 2018
)
3.37
"Pyronaridine-artesunate is a novel ACT."( Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Hine, P; Pryce, J, 2019
)
2.68
"Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine. "( Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.
Ashley, EA; Blessborn, D; Chairat, K; Day, NP; Hanboonkunupakarn, B; Jittamala, P; Lee, SJ; Nosten, F; Panapipat, S; Pukrittayakamee, S; Tarning, J; Thana, P; White, NJ, 2015
)
2.11
"Pyronaridine-artesunate is a promising novel artemisinin-combination therapy for pediatric patients with uncomplicated Plasmodium falciparum malaria, and the development of both the tablet and the granule coformulations is warranted."( Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon.
Bélard, S; Cisse, B; Fleckenstein, L; Glasenapp, Iv; Issifou, S; Kammer, J; Koumba, PK; Kremsner, PG; Kurth, F; Lell, B; Mordmüller, B; Nemeth, J; Oeuvray, C; Ramharter, M; Schlie, M; Schreier, AC, 2008
)
2.18
"Pyronaridine-artesunate is an artemisinin-based combination therapy under evaluation for the treatment of Plasmodium falciparum and P. "( Pyronaridine-artesunate versus mefloquine plus artesunate for malaria.
Abdulla, S; Binh, TQ; Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Pénali, LK; Phyo, AP; Poravuth, Y; Rueangweerayut, R; Shin, CS; Tien, NT; Tinto, H; Uthaisin, C; Valecha, N, 2012
)
3.26
"Pyronaridine is a Mannich base anti-malarial with demonstrated efficacy against drug resistant Plasmodium falciparum, P. "( Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo.
Bongard, E; Croft, SL; Peters, W; Rattray, L; Robinson, BL; Stewart, L; Vivas, L, 2008
)
2.09
"Pyronaridine is an acridine derivative which has been used successfully to treat malaria in China for more than 20 years."( Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa.
Basco, L; Bickii, J; Ringwald, P, 1996
)
1.24
"Pyronaridine is a new antimalarial agent developed in China. "( Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children.
Basco, LK; Bickii, J; Ringwald, P, 1998
)
2.08

Effects

Pyronaridine has been reported as an effective antimalarial over two decades of use in parts of Asia. It is currently being evaluated as a partner drug for artesunate.

ExcerptReferenceRelevance
"Pyronaridine has been reported as an effective antimalarial over two decades of use in parts of Asia, and is currently being evaluated as a partner drug for artesunate."( Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria.
Bukirwa, H; Kramer, CV; Nair, S; Sinclair, D; Tharyan, P; Unnikrishnan, B, 2014
)
1.47
"Pyronaridine has high potency against Plasmodium falciparum, including chloroquine-resistant strains."( Review of pyronaridine anti-malarial properties and product characteristics.
Arbe-Barnes, SJ; Borghini-Fuhrer, I; Craft, JC; Croft, SL; Duparc, S; Fleckenstein, L; Rim, HJ; Shin, CS, 2012
)
1.5
"Pyronaridine has both schizontocidal and gametocytocidal activities against the human malaria parasite, P."( Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro.
Auparakkitanon, S; Chavalitshewinkoon-Petmitr, P; Pongvilairat, G; Wilairat, P, 2000
)
1.32

Treatment

ExcerptReferenceRelevance
"Pyronaridine treatment of mice infected with S."( Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma.
Held, J; Hoffmann, W; Koehne, E; Kreidenweiss, A; Kremsner, PG; Mombo-Ngoma, G; Ramharter, M; Rodi, M; Zander, N; Zoleko-Manego, R, 2021
)
1.58

Toxicity

No evidence that pyronaridine-artesunate re-treatment increased safety risk based on laboratory values, reported adverse event frequencies, or electrocardiograph findings.

ExcerptReferenceRelevance
" Because M-8506 is less toxic than primaquine in mice and more effective in radical treatment of simian malaria, further studies on trifluoroacetyl primaquine are worthy to be considered."( [Tissue schizontocidal action and acute toxicity of trifluoroacetyl primaquine].
Shao, BR; Ye, XY, 1990
)
0.28
" The antimalarial effect of the triple combination on Plasmodium berghei ANKA-infected mice and the toxic effects in mice and rats were additive."( Antimalarial and toxic effect of triple combination of pyronaridine, sulfadoxine and pyrimethamine.
Ha, SH; Huang, J; Huang, ZS; Meng, F; Shao, BR; Shi, XH; Ye, XY; Zhan, CQ, 1989
)
0.52
" In particular, pyronaridine, which is currently being investigated in humans, was metabolized to a compound which was toxic to neutrophils."( Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs.
Maggs, JL; Naisbitt, DJ; O'Neill, PM; Park, BK; Pirmohamed, M; Williams, DP; Willock, DJ, 1998
)
0.87
"0%) adverse events in 849 patients assigned to pyronaridine-artesunate and 241 (57."( Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.
Bedu-Addo, G; Bhatt, KM; Borghini-Fuhrer, I; Bustos, DG; Duparc, S; Fleckenstein, L; Gaye, O; Kayentao, K; Sesay, SS; Shin, CS; Thompson, R; Tjitra, E; Tshefu, AK, 2010
)
0.86
" Adverse events occurred in 57."( Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.
Arbe-Barnes, S; Borghini-Fuhrer, I; Craft, CJ; Duparc, S; Fleckenstein, L; Miller, RM; Shin, CS, 2013
)
0.7
" No evidence was found that pyronaridine-artesunate re-treatment increased safety risk based on laboratory values, reported adverse event frequencies, or electrocardiograph findings."( Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.
Beavogui, AH; Bjorkman, A; Borghini-Fuhrer, I; Borrmann, S; Camara, D; Compaore, YD; Coulibaly, AS; Dara, N; Diallo, MS; Dicko, A; Djimdé, AA; Doumbo, OK; Duparc, S; Fofana, B; Gil, JP; Kabore, MJ; Miller, RM; Nikiema, F; Ouedraogo, JB; Sagara, I; Shin, J; Sirima, SB; Somé, AF; Soulama, I; Sylla, MM; Thera, I; Traore, OB; Zongo, I, 2016
)
0.99
" For quinine, clindamycin, and mefloquine and the combinations of sulfadoxine+pyrimethamine and artemether+lumefantrine, there are reports (including studies without internal comparison groups) that combined describe 304 to >1100 exposures of women in the first trimester for each drug with no conclusive evidence of adverse effects on pregnancy at therapeutic doses."( Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Clark, RL, 2017
)
0.46

Pharmacokinetics

LC-MS technique was found to improve the quantitation of pyronaridine in whole blood. The noncompartmental pharmacokinetic parameters were computed for metoprolol, its metabolite alpha-hydroxymetoprolo, and pyronsaridine.

ExcerptReferenceRelevance
" We conclude that blood is the preferred matrix for clinical pharmacokinetic studies."( Improved assay method for the determination of pyronaridine in plasma and whole blood by high-performance liquid chromatography for application to clinical pharmacokinetic studies.
Chen, YC; Fleckenstein, L, 2001
)
0.57
" This LC-MS technique was found to improve the quantitation of pyronaridine in whole blood allowing its use in pharmacokinetic studies with clinically relevant doses."( Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic studies.
Fleckenstein, L; Imming, P; Murry, DJ; Naik, H; Schmidt, MS, 2007
)
0.79
" Nonlinear mixed-effect modelling was used to obtain the pharmacokinetic and variability (inter-individual and residual variability) parameter estimates."( Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
Craft, JC; Fleckenstein, L; Jang, IJ; Kirsch, LE; Naik, H; Shin, CS; Tan, B; Yu, KS, 2009
)
0.35
"A novel parent-metabolite pharmacokinetic model consisting of a dosing compartment, a central compartment for AS, a central compartment and a peripheral compartment for DHA was developed."( Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
Craft, JC; Fleckenstein, L; Jang, IJ; Kirsch, LE; Naik, H; Shin, CS; Tan, B; Yu, KS, 2009
)
0.35
"A novel simultaneous parent-metabolite pharmacokinetic model with good predictive power was developed to study the population pharmacokinetics of AS and DHA in healthy subjects following single- and multiple-dosing of AS with or without the presence of food."( Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
Craft, JC; Fleckenstein, L; Jang, IJ; Kirsch, LE; Naik, H; Shin, CS; Tan, B; Yu, KS, 2009
)
0.35
" The noncompartmental pharmacokinetic parameters were computed for metoprolol, its metabolite alpha-hydroxymetoprolol, and pyronaridine."( Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol.
Arbe-Barnes, S; Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Lopez-Lazaro, L; Miller, RM; Morris, CA; Pokorny, R; Shin, JS, 2014
)
0.88
" A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs."( Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.
Ashley, EA; Blessborn, D; Chairat, K; Day, NP; Hanboonkunupakarn, B; Jittamala, P; Lee, SJ; Nosten, F; Panapipat, S; Pukrittayakamee, S; Tarning, J; Thana, P; White, NJ, 2015
)
0.67
" Nonlinear mixed-effects modeling using NONMEM software was used to obtain the pharmacokinetic and inter- and intraindividual variability parameter estimates."( Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients.
Ayyoub, A; Borghini-Fuhrer, I; Djimde, AA; Duparc, S; Fleckenstein, L; Methaneethorn, J; Ramharter, M; Shin, JS; Tekete, M, 2015
)
0.7

Compound-Compound Interactions

The in vitro activities of pyronaridine, alone and in combination with established antimalarial drugs, were assessed by isotopic microtest. A multiple dose, parallel group study was conducted to assess for a drug-drug interaction between the pyronsaridine/artesunate (PA) combination antimalaria and ritonavir.

ExcerptReferenceRelevance
"The in vitro activities of pyronaridine, alone and in combination with established antimalarial drugs, were assessed by isotopic microtest."( In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum.
Basco, LK; Bickii, J; Eboumbou, EC; Ringwald, P, 1999
)
0.91
"A multiple dose, parallel group study was conducted to assess for a drug-drug interaction between the pyronaridine/artesunate (PA) combination antimalarial and ritonavir."( Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers.
Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Jung, D; Lopez-Lazaro, L; Methaneethorn, J; Morris, CA; Pokorny, R; Shin, CS, 2012
)
0.87

Bioavailability

ExcerptReferenceRelevance
" The results should guide in formulation of appropriate dosage forms to improve bioavailability of the drug especially from oral routes."( Determination of the physicochemical properties of pyronaridine - a new antimalarial drug.
Adegoke, OA; Babalola, CP; Famuyiwa, AA; Oshitade, OS, 2006
)
0.59
" Pharmacokinetic analysis revealed a dose-dependent increase in the maximum plasma/blood concentration and the area under the curve, as well as comparable relative bioavailability for the granule coformulation."( Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon.
Bélard, S; Cisse, B; Fleckenstein, L; Glasenapp, Iv; Issifou, S; Kammer, J; Koumba, PK; Kremsner, PG; Kurth, F; Lell, B; Mordmüller, B; Nemeth, J; Oeuvray, C; Ramharter, M; Schlie, M; Schreier, AC, 2008
)
0.74
" Pharmacokinetic analysis showed dose linearity, low interindividual variation and absence of a clinically important effect of food on the bioavailability of this drug combination."( Pyronaridine-artesunate combination therapy for the treatment of malaria.
Basra, A; Bélard, S; Kurth, F; Ramharter, M, 2011
)
1.81
" The final parameter estimates of PYR apparent clearance (CL/F), central volume of distribution (V2/F), peripheral volume of distribution (V3/F), intercompartmental clearance (Q/F), and absorption rate constant (Ka) were 377 liters/day, 2,230 liters, 3,230 liters, 804 liters/day and 17."( Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients.
Ayyoub, A; Borghini-Fuhrer, I; Djimde, AA; Duparc, S; Fleckenstein, L; Methaneethorn, J; Ramharter, M; Shin, JS; Tekete, M, 2015
)
0.7
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Pyronaridine-artesunate may become a preferred choice as first-line therapy in malaria endemic regions based on its low cost, long shelf-life, simplified once-daily dosing regimen and proven efficacy.

ExcerptRelevanceReference
" Validation studies with artemisinin demonstrated the need for revising the protocol for the production of the dosing solutions."( In vitro sensitivity of multiresistant Plasmodium falciparum to new candidate antimalarial drugs in western Thailand.
Rooney, W; Schildbach, S; Suebsaeng, L; Wernsdorfer, WH, 1990
)
0.28
"A new oral dosage regimen and formulation of pyronaridine basing on the pharmacokinetic studies and a theoretical dosage regimen reported previously, was clinically evaluated for its therapeutic and undesirable effects on falciparum malaria patients in west Hainan Province, where chloroquine-resistant falciparum malaria was prevalent."( [Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients].
Feng, Z; Guo, RN; Huang, ZS; Lin, X; Meng, F; Xing, QF; Zeng, LH; Zheng, Y, 1989
)
0.85
" To reduce the side effects, another test was carried out in 3 monkeys and the dosage regimen was modified to pyronaridine 6 mg/kg-artemether 10 mg/kg-chloroquine 20 mg/kg (PAC-2) once daily for 3 days."( [Studies on the establishment of malarial animal model of short-term relapse. III. Combined therapy with pyronaridine-artemether-chloroquine for parasitemia clearance].
Fang, Y; Lin, BY; Pan, YR; Zhang, JX; Zheng, H, 1993
)
0.71
" The results should guide in formulation of appropriate dosage forms to improve bioavailability of the drug especially from oral routes."( Determination of the physicochemical properties of pyronaridine - a new antimalarial drug.
Adegoke, OA; Babalola, CP; Famuyiwa, AA; Oshitade, OS, 2006
)
0.59
"A novel parent-metabolite pharmacokinetic model consisting of a dosing compartment, a central compartment for AS, a central compartment and a peripheral compartment for DHA was developed."( Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.
Craft, JC; Fleckenstein, L; Jang, IJ; Kirsch, LE; Naik, H; Shin, CS; Tan, B; Yu, KS, 2009
)
0.35
"Pyronaridine-artesunate - currently under evaluation by the European Medicines Agency - may become a preferred choice as first-line therapy in malaria endemic regions based on its low cost, long shelf-life, simplified once-daily dosing regimen, proven efficacy against falciparum and vivax malaria, and the parallel clinical development of a paediatric drug formulation."( Pyronaridine-artesunate combination therapy for the treatment of malaria.
Basra, A; Bélard, S; Kurth, F; Ramharter, M, 2011
)
3.25
" Patients were randomized (2:1) to pyronaridine-artesunate granules (60/20 mg) once daily or artemether-lumefantrine crushed tablets (20/120 mg) twice daily, both dosed by bodyweight, orally (liquid suspension) for three days."( Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial.
Bhatt, KM; Borghini-Fuhrer, I; Bustos, MD; de Salazar, PM; Doumbo, OK; Duparc, S; Fleckenstein, L; Kayentao, K; Kimani, J; Kokolomami, JH; Offianan, AT; Ouédraogo, A; Pénali, LK; Quicho, F; Ramharter, M; Shin, CS; Tiono, AB; Tshefu, AK, 2012
)
2.1
" Following dosing with PA, some subjects experienced rises in liver function tests above the upper limit of normal during the first few days following PA administration."( Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol.
Arbe-Barnes, S; Borghini-Fuhrer, I; Duparc, S; Fleckenstein, L; Lopez-Lazaro, L; Miller, RM; Morris, CA; Pokorny, R; Shin, JS, 2014
)
0.68
" The aims of this study were to describe the pharmacokinetics of PYR using a total of 1,085 blood PYR concentrations available from 349 malaria patients younger than 16 years of age with mild to moderate uncomplicated malaria and to confirm the dosing regimen for the pediatric granule formulation."( Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients.
Ayyoub, A; Borghini-Fuhrer, I; Djimde, AA; Duparc, S; Fleckenstein, L; Methaneethorn, J; Ramharter, M; Shin, JS; Tekete, M, 2015
)
0.7
" Patients received pyronaridine-artesunate once daily for 3 days, dosed according to body weight."( Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia.
Borghini Fuhrer, I; Canavati, SE; Denis, MB; Dondorp, AM; Duparc, S; Heng, P; Huy, R; Khim, N; Kim, S; Leang, R; Menard, D; Ringwald, P; Tol, B; Vestergaard, LS, 2016
)
1.07
" This may soon change to recommending artemisinin-based combination therapies (standard duration of dosing = 3 days)."( Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Clark, RL, 2017
)
0.46
" All treatments were once-daily or twice-daily tablets or granules given orally and dosed by bodyweight over 3 days at the study centre."( Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
, 2018
)
1.92
" falciparum malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridine-artesunate or artemether-lumefantrine, dosed according to bodyweight, for 3 days."( Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial.
Choy, F; Makio, N; Mens, P; Okach, S; Omweri, G; Osoti, V; Roth, JM; Sawa, P; Schallig, HDFH, 2018
)
2.15
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminoquinolineAny member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency18.55690.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency22.74200.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
Interferon betaHomo sapiens (human)Potency18.55690.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (121)

Assay IDTitleYearJournalArticle
AID1648005Cytotoxicity against HEK293 cells2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID680707TP_TRANSPORTER: increase in Rhodamine 123 intracellular accumulation in K562/A02 cells2004Biochemical and biophysical research communications, Jul-09, Volume: 319, Issue:4
Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo.
AID576576Antimalarial activity against Plasmodium vivax infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1917918Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell viability2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID1574645Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by DAPI staining-based confocal imaging analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1504881Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by DAPI staining based confocal microplate imaging method2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID680903TP_TRANSPORTER: drug resistance (doxorubicin) in K562/A02 cells2004Biochemical and biophysical research communications, Jul-09, Volume: 319, Issue:4
Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo.
AID1661953Antiviral activity against Ebolavirus infected in human HeLa cells assessed as reduction in viral replication incubated for 48 hrs by luminescence based assay2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.
AID576573Antimalarial activity against Plasmodium vivax at the ring stage infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1431589Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP late stage 4 to 5 gametocytes after 48 hrs by MitoTracker Red staining based confocal microscopy2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.
AID576572Antimalarial activity against Plasmodium falciparum trophozoites infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1779233Antimalarial activity against synchronous ring stage of Plasmodium falciparum 3D7 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID576575Antimalarial activity against Plasmodium falciparum infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1648008Selectivity ratio of IC50 for HEK293 cells to IC50 for antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd22020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID158035Inhibitory concentration against Plasmodium falciparum D6 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID1504885Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID158037Inhibitory concentration against Plasmodium falciparum W2 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID235013In vitro therapeutic index value is the ratio between IC50 values of [J] and [P]1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID709177Antimalarial activity against transgenic Plasmodium falciparum 3D7 GFP16B gametocytes2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate.
AID680902TP_TRANSPORTER: drug resistance (doxorubicin) in MCF-7/ADR cells2004Biochemical and biophysical research communications, Jul-09, Volume: 319, Issue:4
Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo.
AID1917919Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter Glo assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID1421917Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 late stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based imaging method2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID772516Antimalarial activity against mature gametocytic stage of Plasmodium falciparum assessed as inhibition of mature gamete exflagellation at 10 uM incubated for 24 hrs prior to exflagellation induction at 21 degC measured after 20 mins by microscopic analysi2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID1732474Antimalarial activity against Plasmodium falciparum NF54 late stage (1 to 3) expressing Pfs16-LUC-GFP assessed as growth inhibition by high content imaging assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.
AID585010Antimalarial activity against Plasmodium malariae ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID1917909Anticancer activity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID1155338Antimalarial activity against late stage gametocyte stage of Plasmodium falciparum NF54 after 72 hrs2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID1917921Inhibition of CAMK1 (unknown origin) at 1 uM by Adapta assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID1917922Inhibition of MELK (unknown origin) at 1 uM by Adapta assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID95454Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID1437504Selectivity index, ratio of IC50 for HEK293 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC
AID1779235Selectivity index, ratio of IC50 for antimalarial activity against Plasmodium falciparum Dd2 to IC50 of antimalarial activity against Plasmodium falciparum 3D72021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1574647Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1917907Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID1685962Antiplasmodial activity against late stage (IV/V) Plasmodium falciparum NF54 gametocytes transfected with GFP-LUC assessed as growth inhibition incubated for 72 hrs by mitotracker Red-CMXROS dye based fluorescence microscopic analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1437499Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method
AID1661954Binding affinity to Ebola virus glycoprotein assessed as dissociation constant incubated for 20 to 30 mins by microscale thermophoresis2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.
AID158039Inhibitory concentration IC50 against Plasmodium falciparum K1 by [3H]hypoxanthine uptake over 24 hr1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID1894272Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 48 hrs by 3H-hypoxanthine incorporation assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID1574649Growth inhibition of HEK293 cells at 40 uM after 72 hrs by resazurin dye based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1431588Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP early stage 1 to 3 gametocytes after 48 hrs by MitoTracker Red staining based confocal microscopy2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.
AID1274589Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1574650Selectivity index, ratio of CC50 for HEK293 cells to IC50 for Plasmodium falciparum 3D72019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1274585Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1437501Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay
AID1355869Antiplasmodial activity against 4-aminoquinoline/antifolates-resistant Plasmodium falciparum Dd2 ring stage infected in human erythrocytes after 72 hrs by DAPI staining based method2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID1574648Growth inhibition of HEK293 cells at 10 uM after 72 hrs by resazurin dye based assay relative to control2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1504889Selectivity index, ratio of IC50 for HEK293 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID772517Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID709179Antimalarial activity against Plasmodium falciparum KT1 gametocytes2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate.
AID585009Antimalarial activity against Plasmodium malariae trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID1431587Antimalarial activity against Plasmodium falciparum NF54 harboring pfs16-LUC-GFP ring stage gametocytes after 24 hrs by MitoTracker Red staining based confocal microscopy2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.
AID1917911Anticancer activity against human SH-SY5Y cells assessed as cell viability at 25 uM incubated for 48 hrs in presence of crizotinib by resazurin dye based fluorescence assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID774658Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1917913Anticancer activity against human SH-SY5Y cells assessed as cell viability at 25 uM incubated for 48 hrs in presence of etoposide by checkerboard assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID1894308Inhibition of Beta-hematin assessed as bis-pyridyl-Fe(III)PPIX complex formation incubated for 5 hrs by NP40 detergent-mediated colorimetric assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID576574Antimalarial activity against Plasmodium vivax trophozoites infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID774663Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1437497Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human RBC after 72 hrs by DAPI staining based confocal microscopic method
AID1732472Antimalarial activity against Plasmodium falciparum NF54 early stage (1 to 3) expressing Pfs16-LUC-GFP assessed as growth inhibition by high content imaging assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID159013Inhibitory concentration against Plasmodium falciparum K1 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID1355868Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage infected in human erythrocytes after 72 hrs by DAPI staining based method2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID1639288Selectivity index, ratio of IC50 for HEK293 cells to IC50 for drug-sensitive Plasmodium falciparum 3D7 ring stage forms2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1274588Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2015Journal of natural products, Dec-24, Volume: 78, Issue:12
Rotenoids, Flavonoids, and Chalcones from the Root Bark of Millettia usaramensis.
AID1648004Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as reduction in parasite growth incubated for 72 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID1450025Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 measured after 72 hrs by DAPI staining based high throughput screening assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID1917916Inhibition of cathepsin D (unknown origin) using MCA labelled GKPILFFRLK(Dnp)-D-R-NH as substrate at 200 uM preincubated for 15 mins followed by substrate addition and measured after 2 hrs by fluorometer analysis2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID1639290Selectivity ratio of IC50 for Plasmodium falciparum Dd2 ring stage forms to IC50 for Plasmodium falciparum 3D7 ring stage forms2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID772515Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID1421916Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 early stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based imaging method2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1639283Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D7 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID774661Antimalarial activity against late (4 to 5) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID1450026Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 measured after 72 hrs by DAPI staining based high throughput screening assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID1450028Growth inhibition of HEK293 cells2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Antiplasmodial β-triketones from the flowers of the Australian tree Angophora woodsiana.
AID1504883Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by DAPI staining based confocal microplate imaging method2017Journal of natural products, 12-22, Volume: 80, Issue:12
Pimentelamines A-C, Indole Alkaloids Isolated from the Leaves of the Australian Tree Flindersia pimenteliana.
AID1355872Cytotoxicity against human HEK293 cells after 72 hrs by resazurin dye based fluorescence assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Antiplasmodial β-Triketone-Flavanone Hybrids from the Flowers of the Australian Tree Corymbia torelliana.
AID1648003Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as reduction in parasite rowth incubated for 72 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID1917920Cytotoxicity against human A549-ACE2 cells expressing ACE2 assessed as reduction in cell viability by CytoTox-Glo assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID585012Antimalarial activity against Plasmodium ovale ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID1917908Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Multiple approaches to repurposing drugs for neuroblastoma.
AID709178Antimalarial activity against Plasmodium falciparum KT3 gametocytes2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate.
AID1574646Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by DAPI staining-based confocal imaging analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID576571Antimalarial activity against Plasmodium falciparum at the ring stage infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1639284Antiplasmodial activity against drug-resistant Plasmodium falciparum Dd2 ring stage forms assessed as inhibition of parasite growth after 72 hrs by DAPI staining-based confocal microscopic analysis2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID576577Antimalarial activity against Plasmodium vivax with >50% parasites at ring stage infected in human erythrocytes assessed as growth inhibition after 30 to 50 hrs by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID1639285Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye-based fluorescence assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
Acrotrione: An Oxidized Xanthene from the Roots of Acronychia pubescens.
AID1779234Antimalarial activity against synchronous ring stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition incubated for 72 hrs by Griffith assay based fluorescence analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Discovery and development of 2-aminobenzimidazoles as potent antimalarials.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (228)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (21.49)18.7374
1990's49 (21.49)18.2507
2000's36 (15.79)29.6817
2010's64 (28.07)24.3611
2020's30 (13.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.44 (24.57)
Research Supply Index5.56 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index72.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (12.07%)5.53%
Reviews15 (6.47%)6.00%
Case Studies1 (0.43%)4.05%
Observational0 (0.00%)0.25%
Other188 (81.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Open-Label Exploratory Study To Determine The Efficacy Of Different Treatment Regimens Of Pyramax® (Pyronaridine-Artesunate) In Asymptomatic Carriers Of Plasmodium Falciparum Monoinfections [NCT03814616]Phase 2300 participants (Actual)Interventional2018-10-03Active, not recruiting
A Phase III Randomised, Double-blind, Double-dummy, Comparative Study to Assess the Safety and Efficacy of Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children and Adult Patients in Korea With Acute P. Vivax Malaria [NCT04368910]Phase 330 participants (Actual)Interventional2007-09-06Terminated(stopped due to Due to slow recruitment the study was terminated prematurely by the Sponsor after 30 subjects had been included)
A Randomised, Double-blind, Placebo Controlled, Parallel Group Study in Healthy Adult Volunteers to Determine the Tolerability and Safety of Pyronaridine (PYR) Co-administered With Piperaquine (PQP) Under Fasted Conditions [NCT05160363]Phase 137 participants (Actual)Interventional2022-02-18Active, not recruiting
Open-label, Drug Interaction Study of Pyronaridine-artesunate and Metoprolol in Healthy Volunteers and Pyronaridine-artesunate Redosing Study in Healthy Volunteers [NCT01523002]Phase 156 participants (Actual)Interventional2012-01-31Completed
Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax®) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia [NCT03726593]Phase 4252 participants (Anticipated)Interventional2018-10-04Recruiting
Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax® [NCT03201770]Phase 48,572 participants (Actual)Interventional2017-06-22Completed
A Human Mass Balance Study of Pyronaridine Using Accelerator Mass Spectrometry [NCT01383109]Phase 16 participants (Actual)Interventional2011-06-30Completed
Comparing Safety and Protective Efficacy of the Whole Plasmodium Falciparum Sporozoite Chemoprophylaxis Vaccine Candidate PfSPZ-CVac and Prime- Target Vaccination With Viral Vectored Vaccine Candidate Regime MVA ME-TRAP/ ChAd63 ME-TRAP in Malaria-naïve, H [NCT05441410]Phase 1/Phase 230 participants (Anticipated)Interventional2024-02-01Not yet recruiting
Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplica [NCT05689047]Phase 2137 participants (Anticipated)Interventional2023-03-29Recruiting
Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection [NCT04264130]Phase 254 participants (Actual)Interventional2018-07-31Completed
An Open-label, Phase II, Dose-Escalation Clinical Study to Assess the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Fixed Dose Combination of Pyronaridine and Artesunate (3:1) in Children With Acute Falciparum Malaria [NCT00331136]Phase 260 participants (Actual)Interventional2006-06-30Completed
A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase Ⅱ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients [NCT04475107]Phase 2113 participants (Actual)Interventional2020-07-09Completed
A Multi-Center Single Arm, Open-label, Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients [NCT05633420]Phase 220 participants (Actual)Interventional2022-07-24Completed
A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria [NCT00440999]Phase 3456 participants (Actual)Interventional2007-03-31Completed
A Phase 2a, Multi-centre, Randomised, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine as an Add-on Therapy in Adults With Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia [NCT05291390]Phase 2200 participants (Anticipated)Interventional2022-11-21Recruiting
Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT00541385]Phase 3535 participants (Actual)Interventional2007-10-31Completed
A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate [NCT05929157]Phase 1/Phase 212 participants (Anticipated)Interventional2023-09-01Not yet recruiting
The Efficacy and Safety of Pyronaridine-artesunate Combined With Low Dose Primaquine for Preventing Transmission of P. Falciparum Gametocytes in Sub-Saharan Africa [NCT04049916]Phase 2/Phase 3100 participants (Actual)Interventional2019-09-12Completed
A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria [NCT00403260]Phase 31,271 participants (Actual)Interventional2007-01-31Completed
A Phase III Comparative (Double-blind, Double-dummy) Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Coartem® (Artemether Lumefantrine) in Children & Adult Patients With Falciparum Malaria [NCT00422084]Phase 31,272 participants (Actual)Interventional2007-01-31Completed
Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 [NCT04532931]Phase 2192 participants (Actual)Interventional2020-09-03Completed
Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers [NCT01156389]Phase 134 participants (Actual)Interventional2010-07-31Completed
Phase I, Randomized, Single Dose, Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet [NCT00682630]Phase 142 participants (Actual)Interventional2007-09-30Completed
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso [NCT04695197]Phase 3142 participants (Anticipated)Interventional2021-01-08Recruiting
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine-artesunate (Artecom®) in COVID-19 Patients [NCT04701606]Phase 2/Phase 3402 participants (Anticipated)Interventional2021-03-29Recruiting
Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Pyronaridine-Artesunate in Healthy Adult Subjects [NCT01552330]Phase 117 participants (Actual)Interventional2012-05-31Completed
Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents With Plasmodium Fa [NCT05974267]Phase 2192 participants (Anticipated)Interventional2023-11-28Recruiting
Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2) [NCT04778813]Phase 41,050 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Comparative Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in The Treatment of Acute Uncomplicated Malaria Among Children In South-West Nigeria [NCT05192265]Phase 2/Phase 3172 participants (Actual)Interventional2019-05-20Completed
Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria [NCT02389439]Phase 2123 participants (Actual)Interventional2015-03-01Completed
A Phase 1b Study to Characterise the Pharmacokinetic/Pharmacodynamic Relationship of Pyronaridine in Healthy Adult Participants Experimentally Infected With Blood Stage Plasmodium Falciparum. [NCT05287893]Phase 110 participants (Actual)Interventional2022-04-04Completed
A Randomised, Multi-Centre, Phase II, Dose-ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT01594931]Phase 2477 participants (Actual)Interventional2005-07-31Completed
Phase 1, Open-label, Cross-over Study to Investigate the Relative Bioavailability of Pyramax (Pyronaridine-artesunate) in Tablet and Granule Formulations, in Healthy Volunteers [NCT01868438]Phase 160 participants (Actual)Interventional2013-05-31Completed
Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya [NCT02411994]Phase 3197 participants (Actual)Interventional2015-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00331136 (8) [back to overview]Number of Patients With PCR-corrected ACPR on Day 42
NCT00331136 (8) [back to overview]Parasite Clearance Time
NCT00331136 (8) [back to overview]Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28
NCT00331136 (8) [back to overview]Number of Patients With PCR-corrected ACPR on Day 14
NCT00331136 (8) [back to overview]Crude ACPR on Day 14, 28 and 42
NCT00331136 (8) [back to overview]Fever Clearance Time
NCT00331136 (8) [back to overview]Number of Subjects With P. Falciparum Gametocytes During the Trial
NCT00331136 (8) [back to overview]Percentage of Patients With Fever Clearance at Day 1, 2 and 3
NCT00403260 (8) [back to overview]Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28
NCT00403260 (8) [back to overview]PCR-corrected ACPR on Day 14
NCT00403260 (8) [back to overview]Parasite Clearance Time
NCT00403260 (8) [back to overview]Fever Clearance Time
NCT00403260 (8) [back to overview]Parasite Clearance at Day 1, 2 and 3
NCT00403260 (8) [back to overview]Fever Clearance at Day 1, 2 and 3
NCT00403260 (8) [back to overview]Crude ACPR on Days 14 and 28
NCT00403260 (8) [back to overview]Adverse Events and Clinically Significant Laboratory Results
NCT00422084 (8) [back to overview]Proportion of Patients With Parasite Clearance at Day 1, 2 and 3
NCT00422084 (8) [back to overview]Fever Clearance Time
NCT00422084 (8) [back to overview]Parasite Clearance Time
NCT00422084 (8) [back to overview]PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14
NCT00422084 (8) [back to overview]PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28
NCT00422084 (8) [back to overview]Adverse Events and Clinically Significant Laboratory Results
NCT00422084 (8) [back to overview]Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28
NCT00422084 (8) [back to overview]Percentage of Patients With Fever Clearance at Day 1, 2 and 3
NCT00440999 (9) [back to overview]Fever Clearance Time
NCT00440999 (9) [back to overview]Parasite Clearance Time
NCT00440999 (9) [back to overview]Number of Participants With Adverse Events
NCT00440999 (9) [back to overview]Percentage of Subjects With Crude and PCR-corrected Cure Rate on Day 42
NCT00440999 (9) [back to overview]Percentage of Subjects With PCR-corrected Cure Rate on Days 14, 21, and 28
NCT00440999 (9) [back to overview]Percentage of Subjects With Fever Clearance on Days 1, 2, and 3
NCT00440999 (9) [back to overview]Crude Cure Rate on Days 21 and 28.
NCT00440999 (9) [back to overview]Percentage of Subjects With Parasite Clearance on Days 1, 2, and 3
NCT00440999 (9) [back to overview]Crude Cure Rate on Day 14
NCT00541385 (8) [back to overview]Percentage of Participants With PCR-Corrected ACPR on Day 14
NCT00541385 (8) [back to overview]Crude ACPR (Non-PCR Corrected ACPR) (Crude Cure Rate) on Day 14 and Day 28
NCT00541385 (8) [back to overview]Parasite Clearance Time
NCT00541385 (8) [back to overview]Proportion of Subjects With Cleared Parasites on Days 1, 2, and 3
NCT00541385 (8) [back to overview]Percentage of Participants With PCR-Corrected ACPR on Day 28
NCT00541385 (8) [back to overview]Proportion of Subjects With Fever Cleared on Days 1, 2, and 3
NCT00541385 (8) [back to overview]Number of Subjects With ≥1 Adverse Event
NCT00541385 (8) [back to overview]Fever Clearance Time
NCT00682630 (5) [back to overview]Pyronaridine Pharmacokinetics: Tmax, Half-life
NCT00682630 (5) [back to overview]Artesunate (AS) and Dihydroartemisinin (DHA) Pharmacokinetics: Tmax, Half-life
NCT00682630 (5) [back to overview]Artesunate (AS) and Dihydroartemisinin (DHA): AUC0-last, AUC0-∞
NCT00682630 (5) [back to overview]Pyronaridine (PP), Artesunate (AS), Dihydroartemisinin (DHA) Pharmacokinetics: Cmax
NCT00682630 (5) [back to overview]Pyronaridine Pharmacokinetics: AUC0-last, AUC0-∞
NCT01156389 (4) [back to overview]Pharmacokinetics Analysis: AUC0-tau, AUC0-∞
NCT01156389 (4) [back to overview]Pharmacokinetics Analysis: Cmax
NCT01156389 (4) [back to overview]Summary of Treatment Emergent Adverse Events
NCT01156389 (4) [back to overview]Pharmacokinetics Analysis: Half-life, Tmax
NCT01383109 (5) [back to overview]Total Radioactivity in Blood: Cmax
NCT01383109 (5) [back to overview]Total Radioactivity in Blood: Half-life, Tmax
NCT01383109 (5) [back to overview]Total Radioactivity in Blood: AUC0-t, AUC0-∞
NCT01383109 (5) [back to overview]Analysis of 14C-Pyronaridine Total Radioactivity in Urine
NCT01383109 (5) [back to overview]Analysis of 14C-Pyronaridine Total Radioactivity in Feces
NCT01523002 (6) [back to overview]Non-WHO Listed Treatment Emergent Adverse Events
NCT01523002 (6) [back to overview]World Health Organization (WHO) Treatment Emergent Adverse Events
NCT01523002 (6) [back to overview]Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: Cmax
NCT01523002 (6) [back to overview]Arm A Pharmacokinetic Parameters of Metoprolol & α-hydroxymetoprolol: Area Under Curve (AUC)0-t, AUC0-∞
NCT01523002 (6) [back to overview]Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: t1/2
NCT01523002 (6) [back to overview]Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: Tmax
NCT01594931 (7) [back to overview]Fever Clearance Time
NCT01594931 (7) [back to overview]Parasite Clearance Time
NCT01594931 (7) [back to overview]PCR-Corrected ACPR at Day 14
NCT01594931 (7) [back to overview]PCR-Corrected ACPR at Day 28
NCT01594931 (7) [back to overview]Adverse Events (AEs)
NCT01594931 (7) [back to overview]Fever Clearance
NCT01594931 (7) [back to overview]Parasite Clearance
NCT01868438 (3) [back to overview]Area Under the Concentration-time Curve From Hour 0 to the Last Sampling Point (AUC 0-t) for Pyronaridine and Dihydroartemisinin (DHA)
NCT01868438 (3) [back to overview]Safety Evaluation - Summary of Adverse Events
NCT01868438 (3) [back to overview]Tmax and Terminal Half Life for Pyronaridine, Artesunate and DHA
NCT04368910 (8) [back to overview]Fever Clearance Time (FCT)
NCT04368910 (8) [back to overview]Crude Cure Rate on Day 42
NCT04368910 (8) [back to overview]Crude Cure Rate on Day 28
NCT04368910 (8) [back to overview]Crude Cure Rate on Day 14
NCT04368910 (8) [back to overview]Percentage of Patients Who Had Cleared Parasite on Days 1, 2, and 3
NCT04368910 (8) [back to overview]Percentage of Patients Who Had Cleared Fever on Days 1, 2, and 3
NCT04368910 (8) [back to overview]Number of Participants With Adverse Events (AEs)
NCT04368910 (8) [back to overview]Parasite Clearance Time (PCT)

Number of Patients With PCR-corrected ACPR on Day 42

Clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 42 days. (NCT00331136)
Timeframe: Day 42

InterventionParticipants (Count of Participants)
Group A (Tablets)10
Group B (Tablets)8
Group C (Tablets)15
Group D (Granules)13

[back to top]

Parasite Clearance Time

The time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of parasites for 2 consecutive negative readings taken between 8 and 24 hours apart. (NCT00331136)
Timeframe: Day 3

Interventionhours (Median)
Group A (Tablets)16.4
Group B (Tablets)16.1
Group C (Tablets)8.1
Group D (Granules)8.3

[back to top]

Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28

Clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 28 days, without previously meeting any of the criteria for early treatment failure, late clinical failure, or late parasitological failure. (NCT00331136)
Timeframe: Day 28

InterventionParticipants (Count of Participants)
Group A (Tablets)11
Group B (Tablets)13
Group C (Tablets)15
Group D (Granules)14

[back to top]

Number of Patients With PCR-corrected ACPR on Day 14

Clearance of asexual parasitaemia within 7 days of initiation of study medication without recrudescence within 14 days. (NCT00331136)
Timeframe: Day 14

InterventionParticipants (Count of Participants)
Group A (Tablets)11
Group B (Tablets)13
Group C (Tablets)15
Group D (Granules)14

[back to top]

Crude ACPR on Day 14, 28 and 42

The proportion of patients with crude (non-PCR corrected) ACPR. (NCT00331136)
Timeframe: Days 14, 28, 42

,,,
InterventionParticipants (Count of Participants)
Day 14Day 28Day 42
Group A (Tablets)11117
Group B (Tablets)13106
Group C (Tablets)151513
Group D (Granules)141412

[back to top]

Fever Clearance Time

"The time from first dosing to the first normal reading with fever clearance, defined as 2 consecutive assessments without fever (<37.5°C) taken between 8 and 24 hours apart.~NB: Time to fever clearance was only summarised for subjects who had fever at baseline or within the first 24 hours after the start of study treatment. Since only 12 subjects in total had fever during this time, the time to fever clearance estimates are not very meaningful." (NCT00331136)
Timeframe: Day 3

Interventionhours (Median)
Group A (Tablets)8.2
Group B (Tablets)8.6
Group C (Tablets)8.2
Group D (Granules)8.2

[back to top]

Number of Subjects With P. Falciparum Gametocytes During the Trial

"The number of gametocytes per μl at Days 0, 3, 7, 14, 21, 28, 35, and 42 summarised from blood slides taken on the respective days.~P. falciparum gametocytes are responsible for transmission from host to vector." (NCT00331136)
Timeframe: Day 42

,,,
InterventionParticipants (Count of Participants)
Baseline>0-24 hours>24-48 hours>48-72 hours>72 hours - Day 7>Day 7 - Day 28>Day 28 - Day 42>Day 42
Group A (Tablets)23222100
Group B (Tablets)01010000
Group C (Tablets)11001000
Group D (Granules)11000000

[back to top]

Percentage of Patients With Fever Clearance at Day 1, 2 and 3

"Patient without fever for 2 consecutive readings taken between 8 and 24 hours apart.~NB: Percentage of fever clearance was only summarised for subjects who had fever at baseline or within the first 24 hours after the start of study treatment. Since only 12 subjects in total had fever during this time, the time to fever clearance estimates are not very meaningful." (NCT00331136)
Timeframe: Days 1, 2, 3

,,,
InterventionParticipants (Count of Participants)
Clearance by >0 - 24 hoursClearance by >24 - 48 hoursClearance by >48 - 72 hoursNo clearance achieved
Group A (Tablets)3000
Group B (Tablets)5000
Group C (Tablets)3000
Group D (Granules)1000

[back to top]

Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00403260)
Timeframe: Day 28

Interventionpercentage of subjects (Number)
Pyronaridine - Artesunate99.2
Mefloquine Plus Artesunate98.1

[back to top]

PCR-corrected ACPR on Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00403260)
Timeframe: Day 14

Interventionpercentage of subjects (Mean)
Pyronaridine - Artesunate99.9
Mefloquine Plus Artesunate99.5

[back to top]

Parasite Clearance Time

Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Thick blood films were examined every 8 hours until ≥72 hours or until 2 consecutive negative readings occurred 7 to 25 hours apart, and on Days 3, 7, 14, 21, 28, 35, and 42 (or any other day if the subject returned).

Interventionhours (Median)
Pyronaridine - Artesunate31.7
Mefloquine Plus Artesunate32.0

[back to top]

Fever Clearance Time

Fever clearance time was defined as the time from first dosing to first normal reading of temperature (<37.5°C taken axillary or tympanic; <38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Every 8 hours over ≥72 hours following first study drug administration or temperature normalisation for ≥2 readings between 7 and 25 hours apart, then at each visit.

Interventionhours (Median)
Pyronaridine - Artesunate15.9
Mefloquine Plus Artesunate16.0

[back to top]

Parasite Clearance at Day 1, 2 and 3

Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00403260)
Timeframe: Days 1, 2 and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (48h after first dose)
Mefloquine Plus Artesunate31.679.890.5
Pyronaridine - Artesunate38.583.891.5

[back to top]

Fever Clearance at Day 1, 2 and 3

Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (<37.5°C axillary/tympanic or <38.0°C oral/rectal) to be obtained within an interval of 7 to 25 hours post-dosing. (NCT00403260)
Timeframe: Days 1, 2 and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Mefloquine Plus Artesunate78.996.298.4
Pyronaridine - Artesunate78.595.999.2

[back to top]

Crude ACPR on Days 14 and 28

Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00403260)
Timeframe: Days 14 and 28

,
Interventionpercentage of subjects (Number)
Cure rate (%) on Day 14Cure rate (%) on Day 28
Mefloquine Plus Artesunate99.596.7
Pyronaridine - Artesunate99.998.7

[back to top]

Adverse Events and Clinically Significant Laboratory Results

Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities (NCT00403260)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life threatenining AENr subj. with ≥1 AE leading to deathNr subj with ≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
Mefloquine Plus Artesunate190943223044
Pyronaridine - Artesunate3891536024055

[back to top]

Proportion of Patients With Parasite Clearance at Day 1, 2 and 3

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00422084)
Timeframe: Days 1, 2, 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
AL Group52.897.299.7
PA Group68.198.199.5

[back to top]

Fever Clearance Time

Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart (NCT00422084)
Timeframe: Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit and as clinically indicated

Interventionhours (Median)
PA Group7.9
AL Group8.0

[back to top]

Parasite Clearance Time

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00422084)
Timeframe: Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned)

Interventionhours (Median)
PA Group23.9
AL Group24.0

[back to top]

PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00422084)
Timeframe: Day 14

Interventionpercentage of subjects (Number)
PA Group99.9
AL Group100

[back to top]

PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00422084)
Timeframe: Day 28

Interventionpercentage of subjects (Number)
PA Group99.5
AL Group99.2

[back to top]

Adverse Events and Clinically Significant Laboratory Results

Incidence of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities. (NCT00422084)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr pat with ≥1 treatment-related SAENr subj. with ≥1 severe or life-threatening AENr subj. with ≥1 AE leading to deathNr subj. ≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
AL Group241123205056
PA Group509275301001619

[back to top]

Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28

Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 28, without correction by PCR, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure. (NCT00422084)
Timeframe: Day 14 and 28

,
Interventionpercentage of subjects (Number)
Cure rate (%) at Day 14Cure rate (%) at Day 28
AL Group10097.2
PA Group10098.9

[back to top]

Percentage of Patients With Fever Clearance at Day 1, 2 and 3

Fever clearance time is defined as the time from first dosing to first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00422084)
Timeframe: Days 1, 2, 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
AL Group87.098.799.3
PA Group88.799.099.5

[back to top]

Fever Clearance Time

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature (<37.5°C for axillary/tympanic or <38°C for oral/rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00440999)
Timeframe: Days 0 to 42

Interventionhours (Median)
Pyronaridine Artesunate15.8
Chloroquine23.8

[back to top]

Parasite Clearance Time

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart. (NCT00440999)
Timeframe: Days 0 to 42

Interventionhours (Median)
Pyronaridine Artesunate23.1
Chloroquine32.0

[back to top]

Number of Participants With Adverse Events

Number of participants with adverse events, including clinically significant laboratory results, ECG, vital signs or physical examination abnormalities. (NCT00440999)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life-threatening AENr subj. with ≥1 AE leading to deathNr subj. ≥1 AE leading to study drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
Chloroquine7223002022
Pyronaridine Artesunate9227200000

[back to top]

Percentage of Subjects With Crude and PCR-corrected Cure Rate on Day 42

Cure on Day 42 is defined as the absence of P. vivax parasitaemia on Day 42 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 42

,
Interventionpercentage of subjects (Number)
Crude cure rate (%)PCR-corrected cure rate (%)
Chloroquine92.194.1
Pyronaridine Artesunate95.595.0

[back to top]

Percentage of Subjects With PCR-corrected Cure Rate on Days 14, 21, and 28

Cure on Days 14, 21, and 28 is defined as the absence of P. vivax parasitaemia on Days 14, 21, and 28 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 14, 21, and 28

,
Interventionpercentage of subjects (Number)
Cure rate (%) at Day 14Cure rate (%) at Day 21Cure rate (%) at Day 28
Chloroquine99.599.597.9
Pyronaridine Artesunate100.0100.098.1

[back to top]

Percentage of Subjects With Fever Clearance on Days 1, 2, and 3

Percentage of subjects with fever clearance on Day 1 (24 hours after first dose), Day 2 (48 hours after first dose), and Day 3 (72 hours after first dose). (NCT00440999)
Timeframe: Day 1, 2, and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Chloroquine58.488.397.4
Pyronaridine Artesunate78.689.997.0

[back to top]

Crude Cure Rate on Days 21 and 28.

Cure on Day 21 and 28 is defined as the absence of P. vivax parasitaemia on Day 21 and 28 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 21 and 28

,
Interventionpercentage of cured subjects (Number)
Cure rate (%) at Day 21Cure rate (%) at Day 28
Chloroquine99.598.0
Pyronaridine Artesunate99.597.1

[back to top]

Percentage of Subjects With Parasite Clearance on Days 1, 2, and 3

Percentage of subjects with parasite clearance on Day 1 (24 hours after first dose), Day 2 (48 hours after first dose), and Day 3 (72 hours after first dose). (NCT00440999)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Chloroquine30.688.096.7
Pyronaridine Artesunate71.699.5100.0

[back to top]

Crude Cure Rate on Day 14

Cure rate on Day 14 is defined as the absence of P. vivax parasitaemia on Day 14 irrespective of temperature (axillary, oral, tympanic, rectal) without previously meeting any of the criteria of treatment failure throughout the follow-up period. (NCT00440999)
Timeframe: Day 14

,
InterventionParticipants (Count of Participants)
Total curedCambodiaIndiaIndonesia/MaumereThailand/Mae SotThailand/Mae Ramatbaseline P. vivax = 250-5,000/uLbaseline P. vivax = >5,000/uL-10,000/uLbaseline P. vivax = >10,000/uLage ≤ 12 yearsage ≥ 12 yearsGender - MaleGender - FemalePrevious P. vivax episode in the past = noPrevious P. vivax episode in the past = yes
Chloroquine2097333104647805970111981486193116
Pyronaridine Artesunate21775331149506958891320416453107110

[back to top]

Percentage of Participants With PCR-Corrected ACPR on Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14. The PCR-corrected ACPR on Day 14 is defined as the absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00541385)
Timeframe: Day 14

Interventionpercentage of subjects (Number)
PA Group100.0
AL Group100.0

[back to top]

Crude ACPR (Non-PCR Corrected ACPR) (Crude Cure Rate) on Day 14 and Day 28

Percentage of subjects with adequate clinical and parasitological response (ACPR) on Day 14 and 28, without correction by PCR. Crude ACPR on Day 14 and 28 is defined as the absence of parasitaemia on Day 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00541385)
Timeframe: Days 14 and 28

,
Interventionpercentage of subjects (Number)
Percentage of Participants with ACPR at Day 14Percentage of Participants with ACPR at Day 28
AL Group10089.2
PA Group10090.2

[back to top]

Parasite Clearance Time

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart (NCT00541385)
Timeframe: Days 0, 3, 7, 14, 21, 28, 35, and 42 or on any other day if the subject spontaneously returned within the 42-day study period

Interventionhours (Median)
PA Group24.1
AL Group24.2

[back to top]

Proportion of Subjects With Cleared Parasites on Days 1, 2, and 3

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart (NCT00541385)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of subjects (Number)
Percentage of Participants with parasite clearance at Day 1 (24h after first dose)Percentage of Participants with parasite clearance at Day 2 (48h after first dose)Percentage of Participants with parasite clearance at Day 3 (72h after first dose)
AL Group43.795.298.8
PA Group49.995.597.0

[back to top]

Percentage of Participants With PCR-Corrected ACPR on Day 28

Percentage of patients with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28. The PCR-corrected ACPR on Day 28 is defined as the absence of parasitaemia on Day 28 without the patient's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT00541385)
Timeframe: Day 28

Interventionpercentage of cured subjects (Number)
PA Group97.6
AL Group98.8

[back to top]

Proportion of Subjects With Fever Cleared on Days 1, 2, and 3

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart (NCT00541385)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of subjects (Number)
Percentage of Participants with fever clearance at Day 1 (24h after first dose)Percentage of Participants with fever clearance at Day 2 (48h after first dose)Percentage of Participants with fever clearance at Day 3 (48h after first dose)
AL Group81.096.898.4
PA Group87.198.599.6

[back to top]

Number of Subjects With ≥1 Adverse Event

(NCT00541385)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life-threatening AENr subj. with ≥1 AE leading to deathNr subj. ≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
AL Group14380002033
PA Group285132102066

[back to top]

Fever Clearance Time

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart. (NCT00541385)
Timeframe: Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit and as clinically indicated (within the 42-day study period)

Interventionhours (Median)
PA Group8.1
AL Group8.1

[back to top]

Pyronaridine Pharmacokinetics: Tmax, Half-life

Tmax: time to maximum concentration Half-life: computed as ln (2)/kel (NCT00682630)
Timeframe: Sampling performed at predose at 0 h and at, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12, 24, 48, 72 h and on Day 5, 7, 14, 21, 28, 35, 42 for each period

,
Interventiondays (Mean)
TmaxHalf-life
Clinical Trial Reference Tablets0.18414.2
To-Be-Marketed Tablets0.16614.1

[back to top]

Artesunate (AS) and Dihydroartemisinin (DHA) Pharmacokinetics: Tmax, Half-life

Tmax: time to maximum concentration Half-life: computed as ln (2)/kel (NCT00682630)
Timeframe: Sampling performed at predose at 0 h and at 0.25, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12 h for each period

,
Interventionhours (Mean)
AS TmaxDHA TmaxAS half-lifeDHA half-life
Clinical Trial Reference Tablets0.4881.140.5491.53
To-Be-Marketed Tablets0.5481.390.5381.84

[back to top]

Artesunate (AS) and Dihydroartemisinin (DHA): AUC0-last, AUC0-∞

AUC0-last: Area under the concentration-time curve from time 0 (0 h) through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn AUC0-∞: Area under the concentration-time curve from time 0 (0 h) to infinity, computed using the linear trapezoidal rule as AUClast + CLQCT / Kel (NCT00682630)
Timeframe: Sampling performed at predose at 0 h and at 0.25, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12 h for each period

,
Interventionng*hr/ml (Mean)
AS AUC0-lastDHA AUC0-lastAS AUC0-∞DHA AUC0-∞9
Clinical Trial Reference Tablets13921501552166
To-Be-Marketed Tablets12121201372143

[back to top]

Pyronaridine (PP), Artesunate (AS), Dihydroartemisinin (DHA) Pharmacokinetics: Cmax

Cmax: maximum peak observed concentration (NCT00682630)
Timeframe: PP sampling performed at predose at at 0 h and at, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12, 24, 48, 72 h and on Day 5, 7, 14, 21, 28, 35, 42 for each period AS, DHA sampling performed at predose at 0 h and at 0.25, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12 h for each period

,
Interventionng/ml (Mean)
PP CmaxAS CmaxDHA Cmax
Clinical Trial Reference Tablets512183987
To-Be-Marketed Tablets533154959

[back to top]

Pyronaridine Pharmacokinetics: AUC0-last, AUC0-∞

AUC0-last: Area under the concentration-time curve from time 0 (0 h) through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn AUC0-∞: Area under the concentration-time curve from time 0 (0 h) to infinity, computed using the linear trapezoidal rule as AUClast + CLQCT / Kel (NCT00682630)
Timeframe: Sampling performed at predose at 0 h and at, 0.5, 1, 1.5, 2.5, 4, 6, 8, 12, 24, 48, 72 h and on Day 5, 7, 14, 21, 28, 35, 42 for each period

,
Interventionng*day/ml (Mean)
AUC0-lastAUC0-∞
Clinical Trial Reference Tablets729877
To-Be-Marketed Tablets762904

[back to top]

Pharmacokinetics Analysis: AUC0-tau, AUC0-∞

"AUC0-tau, AUC0-∞ for pyronaridine, artesunate, DHA:~AUC0-tau - area under the concentration-time curve from Hour 0 to the scheduled time of the next dose AUC0-∞ - area under the concentration-time curve from Hour 0 through the last quantifiable concentration time~Blood samples for pyronaridine analysis were taken at Day 8 predose, Day 9 predose, Day 10 predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose, and Days 11,12, 13, 15, 22, 29, 36 and 43.~Blood samples for artesunate / DHA analysis were taken at Day 10 predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose." (NCT01156389)
Timeframe: Until Day 50 for Arm A and until Day 43 for Arm B

,
Interventionhours*ng/ml (Mean)
Pyronaridine AUC0-tau (adjusted to a common dose of 9.72 mg/kg)Pyronaridine AUC0-∞ (adjusted to a common dose of 9.72 mg/kg)Artesunate AUC0-tau (adjusted to common dose of 3.25 mg/kg)Artesunate AUC0-∞(adjusted to common dose of 3.25 mg/kg)DHA AUC0-tau (adjusted for common 3.25 mg/kg artesunate dose)DHA AUC0-∞ (adjusted for common 3.25 mg/kg artesunate dose)
Arm A Ritonavir Plus Pyramax2291244185.4185.413081310
Arm B Pyramax222131815014919781982

[back to top]

Pharmacokinetics Analysis: Cmax

"Cmax for pyronaridine, artesunate, DHA:~Cmax - maximum peak observed concentration~Blood samples for pyronaridine analysis were taken at Day 8 predose, Day 9 predose, Day 10 predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose, and Days 11,12, 13, 15, 22, 29, 36 and 43.~Blood samples for artesunate / DHA analysis were taken at Day 10 predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose." (NCT01156389)
Timeframe: Until Day 50 for Arm A and until Day 43 for Arm B

,
Interventionng/ml (Mean)
Pyronaridine Cmax (adjusted to a common dose of 9.72 mg/kg)Artesunate Cmax (adjusted to common dose of 3.25 mg/kg)DHA Cmax (adjusted for common 3.25 mg/kg artesunate dose)
Arm A Ritonavir Plus Pyramax480.2128.2611.4
Arm B Pyramax407.5108.7779.2

[back to top]

Summary of Treatment Emergent Adverse Events

Including all the treatment emergent adverse events, the number of subjects discontinued due to adverse events and the number of subjects with serious adverse events. (NCT01156389)
Timeframe: Throughout the study

,
InterventionParticipants (Count of Participants)
Mild treatment emergent adverse eventsModerate treatment emergent adverse eventsSevere treatment emergent adverse eventsSubjects discontinued due to adverse eventsSubjects with serious adverse events
Arm A Ritonavir Plus Pyramax126040
Arm B Pyramax153010

[back to top]

Pharmacokinetics Analysis: Half-life, Tmax

"Half-life and Tmax for pyronaridine, artesunate, DHA:~Tmax - time of the maximum observed concentration Half life - apparent plasma terminal elimination half-life, computed as ln (2)/Kel~Blood samples for pyronaridine analysis were taken at Day 8 predose, Day 9 predose, Day 10 predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose, and Days 11,12, 13, 15, 22, 29, 36 and 43.~Blood samples for artesunate / DHA analysis were taken at Day 10 predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours postdose." (NCT01156389)
Timeframe: Until Day 50 for Arm A and until Day 43 for Arm B

,
Interventionhours (Mean)
Pyronaridine half- life (adjusted to a common dose of 9.72 mg/kg)Pyronaridine Tmax (adjusted to a common dose of 9.72 mg/kg)Artesunate half-life (adjusted to common dose of 3.25 mg/kg)Artesunate Tmax (adjusted to common dose of 3.25 mg/kg)DHA half-life (adjusted for common 3.25 mg/kg artesunate dose)DHA Tmax (adjusted for common 3.25 mg/kg artesunate dose)
Arm A Ritonavir Plus Pyramax3842.320.4251.222.271.90
Arm B Pyramax321.61.440.4650.842.351.44

[back to top]

Total Radioactivity in Blood: Cmax

"Pharmacokinetic Parameters:~Cmax: maximum observed peak observed concentration~PK sampling performed at predose, 0.5, 1, 2, 4, 8, 12 and 24 hours, and 2, 4, 6, 7, 14, 21, 28, 35 and 42 days post-dose" (NCT01383109)
Timeframe: 42 days

Interventionng-eq/ml (Mean)
Pyronaridine271

[back to top]

Total Radioactivity in Blood: Half-life, Tmax

"Pharmacokinetic Parameters:~Half-life: computed as ln (2) / Kel Tmax: time to maximum concentration~PK sampling performed at predose, 0.5, 1, 2, 4, 8, 12 and 24 hours, and 2, 4, 6, 7, 14, 21, 28, 35 and 42 days post-dose" (NCT01383109)
Timeframe: 42 days

Interventiondays (Mean)
Half-lifeTmax
Pyronaridine33.50.111

[back to top]

Total Radioactivity in Blood: AUC0-t, AUC0-∞

"Pharmacokinetic Parameters:~AUC0-t: area under the plasma concentration-time curve from Hour 0 through the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was collected AUC0-∞: area under the plasma concentration-time curve from Hour 0 to infinity~PK sampling performed at predose, 0.5, 1, 2, 4, 8, 12 and 24 hours, and 2, 4, 6, 7, 14, 21, 28, 35 and 42 days post-dose" (NCT01383109)
Timeframe: 42 days

Interventionday*ng-eq/ml (Mean)
AUC0-tAUC0-∞
Pyronaridine18343731

[back to top]

Analysis of 14C-Pyronaridine Total Radioactivity in Urine

"Radioactivity recovery in urine as a percent of the administered dose.~Continuous collection of samples was performed through 168 hours post-dose, with intermittent 48 hour collections occurring thereafter" (NCT01383109)
Timeframe: 2064 hours

Intervention% administered dose (Mean)
0-4h4-8h8-24h24-48h48-72h72-96h96-120h120-144h144-168h168-336h336-384h384-504h504-552h552-672h672-720h720-840h840-888h888-1008h1008-1056h1056-1344h1344-1392h1392-1680h1680-1728h1728-2016h2016-2064h
Pyronaridine0.090.160.600.710.670.630.550.550.603.872.382.380.841.810.611.340.461.110.422.080.271.420.201.120.17

[back to top]

Analysis of 14C-Pyronaridine Total Radioactivity in Feces

"Radioactivity recovery in feces as a percent of the administered dose.~Continuous collection of samples was performed through 168 hours post-dose, with intermittent 48 hour collections occurring thereafter" (NCT01383109)
Timeframe: 2064 hours

Intervention% administered dose (Mean)
24-48h48-72h72-96h96-120h120-144h144-168h168-336h336-384h384-504h504-552h552-672h672-720h720-840h840-888h888-1008h1008-1056h1056-1344h1344-1392h1392-1680h1680-1728h1728-2016h2016-2064h
Pyronaridine7.3112.785.834.532.112.037.891.402.690.761.580.511.010.300.700.261.230.150.680.090.410.07

[back to top]

Non-WHO Listed Treatment Emergent Adverse Events

To assess the safety of redosing a 3-day regimen of pyronaridine-artesunate (NCT01523002)
Timeframe: 140 days

,
Interventionparticipants (Number)
MildModerateSevereLife-threatening
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing23500
Arm B: Pyronaridine-artesunate 60-day Redosing211400

[back to top]

World Health Organization (WHO) Treatment Emergent Adverse Events

To assess the safety of redosing a 3-day regimen of pyronaridine-artesunate. Grade 1: mild adverse event Grade 2: moderate adverse event Grade 3: severe and undesirable adverse event Grade 4: life threatening adverse event Grade 5: fatal adverse event resulting in death (NCT01523002)
Timeframe: 140 days

,
Interventionparticipants (Number)
Grade 1 toxicityGrade 2 toxicityGrade 3 toxicityGrade 4 toxicity
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing251220
Arm B: Pyronaridine-artesunate 60-day Redosing241742

[back to top]

Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: Cmax

"Cmax of Metoprolol & α-hydroxymetoprolol for Period 1 (metoprolol alone) & Period 2 (pyronaridine-artesunate with metoprolol)~Abbreviations: Cmax = maximum peak observed concentration" (NCT01523002)
Timeframe: Plasma samples taken predose and following metoprolol dosing at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose on Days 1 & 10

Interventionhours (Geometric Mean)
Period 1 Cmax MetoprololPeriod 2 Cmax MetoprololPeriod 1 Cmax α-hydroxymetoprololPeriod 2 Cmax α-hydroxymetoprolol
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing152.7228.673.966.8

[back to top]

Arm A Pharmacokinetic Parameters of Metoprolol & α-hydroxymetoprolol: Area Under Curve (AUC)0-t, AUC0-∞

"AUC0-t & AUC0-∞ of Metoprolol & α-hydroxymetoprolol for Period 1 (metoprolol alone) & Period 2 (pyronaridine-artesunate with metoprolol)~Abbreviations: AUC = area under the concentration-time curve; AUC0-t = AUC from Hour 0 to the last quantifiable concentration time (LQCT), where LQCT is the time at which the last sample with a quantifiable concentration was drawn; AUC0-∞ = AUC from Hour 0 to infinity" (NCT01523002)
Timeframe: Plasma samples taken predose and following metoprolol dosing at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose on Days 1 & 10

Interventionng.h/ml (Geometric Mean)
Period 1 AUC0-t MetoprololPeriod 1 AUC0-∞ MetoprololPeriod 2 AUC0-t MetoprololPeriod 2 AUC0-∞ MetoprololPeriod 1 AUC0-t α-hydroxymetoprololPeriod 1 AUC0-∞ α-hydroxymetoprololPeriod 2 AUC0-t α-hydroxymetoprololPeriod 2 AUC0-∞ α-hydroxymetoprolol
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing685746895958707804601739

[back to top]

Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: t1/2

"t1/2 of Metoprolol & α-hydroxymetoprolol for Period 1 (metoprolol alone) & Period 2 (pyronaridine-artesunate with metoprolol)~Abbreviations: t1/2 = apparent terminal phase half-life" (NCT01523002)
Timeframe: Plasma samples taken predose and following metoprolol dosing at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose on Days 1 & 10

Interventionhours (Geometric Mean)
Period 1 t1/2 MetoprololPeriod 2 t1/2 MetoprololPeriod 1 t1/2 α-hydroxymetoprololPeriod 2 t1/2 α-hydroxymetoprolol
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing3.393.287.347.55

[back to top]

Arm A Pharmacokinetics Parameters of Metoprolol & α-hydroxymetoprolol: Tmax

"tmax of Metoprolol & α-hydroxymetoprolol for Period 1 (metoprolol alone) & Period 2 (pyronaridine-artesunate with metoprolol)~Abbreviations: tmax = time to maximum observed concentration." (NCT01523002)
Timeframe: Plasma samples taken predose and following metoprolol dosing at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours postdose on Days 1 & 10

Interventionhours (Median)
Period 1 tmax MetoprololPeriod 2 tmax MetoprololPeriod 1 tmax α-hydroxymetoprololPeriod 2 tmax α-hydroxymetoprolol
Arm A: Metoprolol DDI and Pyronaridine-artesunate 90-day Redosing1.51.001.51.5

[back to top]

Fever Clearance Time

Fever clearance time was defined as the time (in hours) from first dosing to the first normal reading with fever clearance (2 consecutive assessments without fever (<37.5°C)). The method of temperature measurement was the same (ie, axillary, tympanic, oral or rectal) for each subject. Any subjects with a documented history of fever at inclusion, but who did not subsequently have a documented temperature reading >37.5°C during the 24 hours after initial dosing, were not included in this end point analysis. (NCT01594931)
Timeframe: Every 8 hours for at least 72 hours after the first dose

Interventionhours (Mean)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)16.8
Group B: Pyronaridine/Artesunate (9:3 mg/kg)24.0
Group C: Pyronaridine/Artesunate (12:4 mg/kg)17.0

[back to top]

Parasite Clearance Time

Parasite clearance time was defined as the time (in hours) from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of parasites for two consecutive negative readings eight hours apart, with confirmed negative reading at 24 hours after the first negative slide (NCT01594931)
Timeframe: Thick blood slides were examined every 8 hours until at least 72 hours or until a negative smear was recorded

Interventionhours (Mean)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)36.9
Group B: Pyronaridine/Artesunate (9:3 mg/kg)33.6
Group C: Pyronaridine/Artesunate (12:4 mg/kg)30.8

[back to top]

PCR-Corrected ACPR at Day 14

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT01594931)
Timeframe: Day 14

Interventionpercentage of subjects (Number)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)100
Group B: Pyronaridine/Artesunate (9:3 mg/kg)100
Group C: Pyronaridine/Artesunate (12:4 mg/kg)100

[back to top]

PCR-Corrected ACPR at Day 28

Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure (NCT01594931)
Timeframe: Day 28

Interventionpercentage of subjects (Number)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)95
Group B: Pyronaridine/Artesunate (9:3 mg/kg)99
Group C: Pyronaridine/Artesunate (12:4 mg/kg)99

[back to top]

Adverse Events (AEs)

An AE was defined as any unfavourable and unintended sign, symptom, syndrome, or illness that developed or worsened during the period of observation in the clinical study (NCT01594931)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

,,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 AE leading to deathNr subj. with ≥1 AE leading to study withdrawal
Group A: Pyronaridine/Artesunate (6:2 mg/kg)106353003
Group B: Pyronaridine/Artesunate (9:3 mg/kg)90330001
Group C: Pyronaridine/Artesunate (12:4 mg/kg)91361101

[back to top]

Fever Clearance

Fever clearance was defined as a subject without fever for 2 consecutive assessments, plus confirmed normal temperature at 24 hours. The proportion of subjects with fever clearance was summarized at Days 1, 2, and 3. (NCT01594931)
Timeframe: Days 1, 2 and 3

,,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)969999
Group B: Pyronaridine/Artesunate (9:3 mg/kg)919696
Group C: Pyronaridine/Artesunate (12:4 mg/kg)96100100

[back to top]

Parasite Clearance

Parasite clearance is defined as zero presence of parasites for 2 consecutive negative readings 8 hours apart, with confirmed negative reading at 24 hours after the first negative slide. The proportion of subjects with parasite clearance was summarized at Days 1, 2, and 3. (NCT01594931)
Timeframe: Days 1, 2, and 3

,,
Interventionpercentage of subjects (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Group A: Pyronaridine/Artesunate (6:2 mg/kg)749396
Group B: Pyronaridine/Artesunate (9:3 mg/kg)829698
Group C: Pyronaridine/Artesunate (12:4 mg/kg)849599

[back to top]

Area Under the Concentration-time Curve From Hour 0 to the Last Sampling Point (AUC 0-t) for Pyronaridine and Dihydroartemisinin (DHA)

Pharmacokinetic blood sampling for first or second intervention dose (NCT01868438)
Timeframe: First intervention: Day 1 pre-dose to Day 43 visit (D1, 2, 3, 4, 6, 8, 15, 22, 29, 36, 43) ; second intervention: Day 61 pre-dose to Day 103 visit (D61, 62, 63, 64, 66, 68, 75, 82, 89, 96, 103)

,
Interventionng*h/ml (Mean)
AUC 0-t pyronaridineAUC 0-t DHA
Total Receiving Pyronaridine-artesunate Granules11324829
Total Receiving Pyronaridine-artesunate Tablets116401119

[back to top]

Safety Evaluation - Summary of Adverse Events

(NCT01868438)
Timeframe: End of study (Day 103)

,
InterventionParticipants (Count of Participants)
Adverse event before treatmentTreatment-emergent adverse eventTreatment-related adverse eventSerious adverse eventSerious adverse drug reactionAdverse event leading to discontinuation
Total Receiving Pyronaridine-artesunate Granules02314003
Total Receiving Pyronaridine-artesunate Tablets22214003

[back to top]

Tmax and Terminal Half Life for Pyronaridine, Artesunate and DHA

Pharmacokinetic blood sampling for first or second intervention dose (NCT01868438)
Timeframe: First intervention: Day 1 pre-dose to Day 43 visit (D1, 2, 3, 4, 6, 8, 15, 22, 29, 36, 43) ; second intervention: Day 61 pre-dose to Day 103 visit (D61, 62, 63, 64, 66, 68, 75, 82, 89, 96, 103)

,
Interventionhours (Mean)
Tmax pyronaridineHalf-life pyronaridineTmax artesunateHalf-life artesunateTmax DHAHalf-life DHA
Total Receiving Pyronaridine-artesunate Granules1.7591.81.520.712.261.43
Total Receiving Pyronaridine-artesunate Tablets2.16390.980.331.461.50

[back to top]

Fever Clearance Time (FCT)

Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart (NCT04368910)
Timeframe: Day 0 and every 8 hours over ≥72 hours following first study drug administration or temperature normalization for ≥2 readings between 7 and 25 hours apart, then at each visit (Days 7, 14, 28 and 42)

Interventionhours (Median)
Pyronaridine - Artesunate16.0
Chloroquine31.9

[back to top]

Crude Cure Rate on Day 42

Proportion of subjects with crude cure rate at Day 42, defined as absence of parasitaemia on Day 42, irrespective of body temperature without previously meeting any of the criteria of treatment failure (NCT04368910)
Timeframe: Day 42

Interventionpercentage of subjects (Number)
Pyronaridine - Artesunate100
Chloroquine100

[back to top]

Crude Cure Rate on Day 28

Percentage of subjects with crude cure rate at Day 28, defined as absence of parasitaemia on Day 28, irrespective of body temperature without previously meeting any of the criteria of treatment failure (NCT04368910)
Timeframe: Day 28

Interventionpercentage of participants (Number)
Pyronaridine - Artesunate100
Chloroquine100

[back to top]

Crude Cure Rate on Day 14

Percentage of subjects with crude cure rate at Day 14, defined as absence of parasitaemia on Day 14, irrespective of body temperature without previously meeting any of the criteria of treatment failure (NCT04368910)
Timeframe: Day 14

Interventionpercentage of participants (Number)
Pyronaridine - Artesunate100
Chloroquine100

[back to top]

Percentage of Patients Who Had Cleared Parasite on Days 1, 2, and 3

Parasite clearance is defined as at least 2 consecutive negative smears for asexual parasites obtained within an interval of 7 to 25 hours post-dosing (NCT04368910)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of participants (Number)
Day 1 (24h after first dose)Day 2 (48h after first dose)Day 3 (72h after first dose)
Chloroquine0.026.760.0
Pyronaridine - Artesunate30.892.3100.0

[back to top]

Percentage of Patients Who Had Cleared Fever on Days 1, 2, and 3

Fever clearance is defined as at least 2 consecutive normal body temperature measurements (<37.5 C axillary/tympanic or <38.0 C oral/rectal) obtained within an interval of 7 to 25 hours postdosing (NCT04368910)
Timeframe: Days 1, 2, and 3

,
Interventionpercentage of participants (Number)
Clearance rate (%) at Day 1 (24h after first dose)Clearance rate (%) at Day 2 (48h after first dose)Clearance rate (%) at Day 3 (72h after first dose)
Chloroquine41.791.7100.0
Pyronaridine - Artesunate76.992.3100.0

[back to top]

Number of Participants With Adverse Events (AEs)

Number of Participants with AEs, including clinically significant laboratory results, electrocardiogram (ECG), vital signs or physical examination abnormalities (NCT04368910)
Timeframe: Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study

,
InterventionParticipants (Count of Participants)
Nr subj. with ≥1 AENr subj. with ≥1 treatment-related AENr subj. with ≥1 SAENr subj. with ≥1 treatment-related SAENr subj. with ≥1 severe or life-threatening AENr subj. with ≥1 AE leading to deathNr subj. with≥1 AE leading to drug discontinuationNr subj. with ≥1 AE leading to study withdrawal
Chloroquine109002000
Pyronaridine - Artesunate107000000

[back to top]

Parasite Clearance Time (PCT)

Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart (NCT04368910)
Timeframe: Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned within the 42-day period)

Interventionhours (Median)
Pyronaridine - Artesunate32.0
Chloroquine63.9

[back to top]